
Summary Esophageal adenocarcinoma incidence has risen dramatically in the Western world over the past 30 years, particularly driven by gastroesophageal reflux disease (GERD) and Barrett’s esophagus (BE). We aimed to assess whether Volatile Organic Compound (VOC) breath testing can predict BE and to validate its performance in independent cohorts including participants with BE, participants with GERD, and controls. Participants aged ≥18 years referred for gastroscopy between August 2017 and July 2022, were eligible for inclusion. The diagnostic accuracy of VOC breath testing was assessed using four machine learning algorithms (MLAs): (1) random forest, (2) extremely randomized trees, (3) eXtreme Gradient Boosting (XGBoost), and (4) convolutional neural network. Patient tolerability and patient acceptability of breath testing were secondary outcome measures. A total of 1079 participants were included, 602 (55.8%) in the training cohort and 477 (44.2%) in the validation cohort. In the training cohort, XGBoost was the best performing MLA in differentiating BE from GERD and controls (area under the receiver operating characteristic [AUROC] 0.892 [95% CI, 0.862–0.921]). However, in the validation cohort, the performance of XGBoost markedly declined (AUROC 0.530 [95% CI, 0.472–0.589]). Median tolerability score was 2.00 with 0 ‘no discomfort’ and 10 ‘worst discomfort imaginable’, and median acceptability score was 8.00 with 0 ‘worst experience’ and 10 ‘best experience’. VOC breath testing in its current form does not provide additional diagnostic value for BE screening; however, based on the high degree of patient acceptability, further research on eNose technology seems justified.
Barrett's esophagus (BE) is the only recognized precursor to esophageal adenocarcinoma (EAC). Endoscopic monitoring of BE allows for early detection and prevention against advanced cancer, which carries high morbidity and mortality. Over the past two decades, management of early EAC has shifted from esophagectomy toward organ-preserving endoscopic eradication therapy (EET), including endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and ablative modalities such as radiofrequency ablation, cryotherapy, and hybrid argon plasma coagulation. EMR remains standard for most lesions with pre-invasive neoplasia and small intramucosal EAC, while ESD provides technical advantages for larger or complex neoplasia, though comparative long-term outcome data are limited. Ablation after resection achieves durable clearance of dysplasia and intestinal metaplasia, with emerging therapies showing promise in refractory or high-risk cases. Structured post-EET surveillance is critical, as recurrence risk is highest within 1-2 years of achieving remission, but persists at lower levels long-term. The risk of recurrence is influenced by lesion characteristics, treatment strategy, and center experience. Personalized, risk-adapted surveillance is increasingly supported, incorporating clinical factors such as BE length, baseline histology and prior treatment. More recently, molecular biomarkers and artificial intelligence (AI)-driven integration of clinical and genomic features have shown promising results. Future research should optimize tissue acquisition, refine biomarker panels, and validate AI-enabled predictive models to improve patient selection, minimize recurrence, and guide cost-effective, individualized care.